Fenlu Zhu

856 total citations · 1 hit paper
21 papers, 593 citations indexed

About

Fenlu Zhu is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Fenlu Zhu has authored 21 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Fenlu Zhu's work include CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Fenlu Zhu is often cited by papers focused on CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Fenlu Zhu collaborates with scholars based in United States, Germany and China. Fenlu Zhu's co-authors include Parameswaran Hari, Carolyn A. Keever-Taylor, Nirav N. Shah, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Bryon D. Johnson, Timothy S. Fenske, Mehdi Hamadani and Winfried Krueger and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Fenlu Zhu

21 papers receiving 582 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

2020 318 citations Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine profile →

Peers

Countries citing papers authored by Fenlu Zhu

Since Specialization

Citations

This map shows the geographic impact of Fenlu Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fenlu Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fenlu Zhu more than expected).

Fields of papers citing papers by Fenlu Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fenlu Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fenlu Zhu. The network helps show where Fenlu Zhu may publish in the future.

Co-authorship network of co-authors of Fenlu Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Fenlu Zhu. A scholar is included among the top collaborators of Fenlu Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fenlu Zhu. Fenlu Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation 2022 ·Brain Behavior & Immunity - Health ·Mallory Taylor, Cecilia J. Hillard, William R. Drobyski, Anikó Szabó, Bryon D. Johnson, Fenlu Zhu, Charles L. Raison, Steve W. Cole, Jennifer M. Knight	1
2	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial breakdown → 2020 ·Nature Medicine ·Nirav N. Shah, Bryon D. Johnson, Dina Schneider, Fenlu Zhu, Anikó Szabó, Carolyn A. Keever-Taylor, Winfried Krueger, Andrew Worden, Michael J. Kadan, Sharon Yim, Ashley M. Cunningham, Mehdi Hamadani, Timothy S. Fenske, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari	318
3	A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis after Allogeneic Transplantation (alloHCT). 2019 ·Biology of Blood and Marrow Transplantation ·Saurabh Chhabra, Parameswaran Hari, Alexis Visotcky, Fenlu Zhu, (unknown), Sameem Abedin, Binod Dhakal, Anita D’Souza, William R. Drobyski, Timothy S. Fenske, James H. Jerkins, J. Douglas Rizzo, Lyndsey Runaas, Wael Saber, Nirav N. Shah, Bronwen E. Shaw, Marcelo C. Pasquini, Mehdi Hamadani	1
4	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma 2019 ·Blood ·Nirav N. Shah, Fenlu Zhu, Dina Schneider, Winfried Krueger, Andrew Worden, Walter Longo, Mehdi Hamadani, Timothy S. Fenske, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari, Bryon D. Johnson	7
5	Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL 2019 ·Biology of Blood and Marrow Transplantation ·Fenlu Zhu, Nirav N. Shah, Dina Schneider, Huiqing Xu, (unknown), (unknown), Carolyn A. Keever-Taylor, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari, Bryon D. Johnson	2
6	Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. 2019 ·Journal of Clinical Oncology ·Nirav N. Shah, Fenlu Zhu, Dina Schneider, Carolyn Taylor, Winfried Krueger, Andrew Worden, Walter Longo, Mehdi Hamadani, Timothy S. Fenske, Bryon D. Johnson, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari	32
7	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- versus -host disease: low incidence of lower gastrointestinal tract disease 2018 ·Haematologica ·William R. Drobyski, Anikó Szabó, Fenlu Zhu, Carolyn A. Keever-Taylor, Kyle Hebert, (unknown), Sharon Yim, Bryon D. Johnson, Anita D’Souza, Mary Eapen, Timothy S. Fenske, Parameswaran Hari, Mehdi Hamadani, Mary M. Horowitz, J. Douglas Rizzo, Wael Saber, Nirav N. Shah, Bronwen E. Shaw, Marcelo C. Pasquini	32
8	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma 2018 ·Blood ·Nirav N. Shah, Fenlu Zhu, Carolyn Taylor, Dina Schneider, Winfried Krueger, Andrew Worden, Sharon Yim, Timothy S. Fenske, Mehdi Hamadani, Bryon D. Johnson, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari	27
9	Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL 2018 ·Blood ·Fenlu Zhu, Nirav N. Shah, Dina Schneider, Huiqing Xu, (unknown), (unknown), Carolyn A. Keever-Taylor, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari, Bryon D. Johnson	5
10	Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center 2017 ·Cytotherapy ·Fenlu Zhu, Nirav N. Shah, Huiqing Xu, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Parameswaran Hari, Carolyn A. Keever-Taylor	87
11	Dual Targeted CD20/19 CAR-T Cell Production Using the ClinimacsÂ® Prodigy System 2017 ·Biology of Blood and Marrow Transplantation ·Nirav N. Shah, Fenlu Zhu, Huiqing Xu, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Parameswaran Hari, Carolyn A. Keever-Taylor	1
12	CAR-T Cell Production Using the Clinimacs® Prodigy System 2016 ·Blood ·Fenlu Zhu, Nirav N. Shah, Huiqing Xu, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Parameswaran Hari, Carolyn A. Keever-Taylor	14
13	Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products 2015 ·Cytotherapy ·Fenlu Zhu, (unknown), Joanne Kurtzberg, Barbara Waters‐Pick, Parameswaran Hari, David A. Margolis, Carolyn A. Keever-Taylor	11
14	Generation of cytotoxic T-cell lines using overlapping pentadecapeptides derived from conserved regions of the adenovirus hexon protein 2010 ·Journal of General Virology ·Fenlu Zhu, Huan Xu, (unknown), David A. Margolis, Carolyn A. Keever-Taylor	4
15	Stimulation by means of dendritic cells followed by Epstein–Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses 2007 ·Clinical & Experimental Immunology ·Fenlu Zhu, Gamal Ramadan, (unknown), David A. Margolis, Carolyn A. Keever-Taylor	18
16	Interactions between helper T-cell epitopes of hepatitis C virus 2005 ·Vaccine ·Fenlu Zhu, Meiying Yang, David D. Eckels	4
17	Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line 2004 ·Vaccine ·Meiying Yang, Fenlu Zhu, Grete Sønderstrup, David D. Eckels	4
18	Selection of trkB-binding peptides from a phage-displayed random peptide library 2003 ·Science in China Series C Life Sciences ·(unknown), Xiaolan Wu, Mingmei Cao, Wei Pan, Fenlu Zhu, Jingshan Chen, Zhongtian Qi	5
19	Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL 2002 ·Human Immunology ·Fenlu Zhu, David D. Eckels	13
20	A Preliminary Study on Macaca Mulatta Infected by Intrahepatic Injection of GHV-C/HGV RNA Transcripts Produced in vitro 2000 ·Fenlu Zhu	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact